Patient Square Capital’s Kymera Therapeutics KYMR Stock Holding History

Patient Square Capital’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.33M	Sell	100,000 -39,000	-28%	-$3.09M	1.48%	19
2025 Q4	$10.8M	Buy	139,000 +46,408	+50%	+$3.13M	2.32%	12
2025 Q3	$5.24M	Sell	92,592 -47,408	-34%	-$2.14M	1.4%	12
2025 Q2	$6.11M	Sell	140,000 -2,201	-2%	-$75.8K	2.2%	8
2025 Q1	$3.89M	Buy	+142,201	New	+$5.18M	1.61%	13

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Patient Square Capital's KYMR Position: Q1 2026 in Review

Patient Square Capital reduced its Kymera Therapeutics (KYMR) stake by 28% in Q1 2026, selling an estimated $3.09M and leaving 100,000 shares worth $8.33M. The position accounts for 1.48% of the portfolio, ranked #19.

Patient Square Capital first reported a position in KYMR in Q1 2025 and has held it in 5 quarters since. The position peaked at $10.8M in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

Patient Square Capital held 100,000 shares of Kymera Therapeutics worth $8.33M as of Q1 2026.
Patient Square Capital sold 39,000 Kymera Therapeutics shares in Q1 2026, an estimated $3.09M.
Kymera Therapeutics made up 1.48% of Patient Square Capital's portfolio in Q1 2026, its #19 holding.
Patient Square Capital first reported a position in Kymera Therapeutics in Q1 2025 and has held it in 5 quarters since.
Patient Square Capital's Kymera Therapeutics position peaked at $10.8M in Q4 2025.
256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Patient Square Capital's 13F filing for Q1 2026, filed 15 May 2026.